Matricelf Advances Toward First in Human Trial Following Successful GLP Safety Study Completion

TEL AVIV, Israel, June 17, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered tissue implants for spinal cord injury, today announced the successful completion of its comprehensive GLP safety study for its engineered neural...